Abiopharma

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-10-24 AccNo: 0001575872-25-000633 Size: 1 MB

Northwest Biotherapeutics Announces that its Acquisition of Advent BioServices Ltd. has Closed

A New Press Release from Theriva Biologics, Inc.

Syndax Announces FDA Approval of Revuforj®(revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman

New Form 3 - Protagenic Therapeutics, Inc.\new Filed: 2025-10-24 AccNo: 0001096906-25-001711 Size: 11 KB

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-10-24 AccNo: 0001575872-25-000631 Size: 1 MB

New Form 6-K - I-Mab Filed: 2025-10-24 AccNo: 0001193125-25-249612 Size: 8 MB

Cogent Biosciences Announces KRAS PosterPresentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

(99% Neutral) Northwest Biotherapeutics, Inc. (NWBO) Provides Business Update

Law Offices of Howard G. Smith Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith Encourages Baxter International, Inc. (BAX) Shareholders To Inquire About Securities Fraud Class Action